249 related articles for article (PubMed ID: 9617508)
41. A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome.
Garcia-Borreguero D; Grunstein R; Sridhar G; Dreykluft T; Montagna P; Dom R; Lainey E; Moorat A; Roberts J
Sleep Med; 2007 Nov; 8(7-8):742-52. PubMed ID: 17512789
[TBL] [Abstract][Full Text] [Related]
42. Pramipexole, ropinirole, and mania in Parkinson's disease.
Singh A; Althoff R; Martineau RJ; Jacobson J
Am J Psychiatry; 2005 Apr; 162(4):814-5. PubMed ID: 15800169
[No Abstract] [Full Text] [Related]
43. Treatment of Parkinson's disease: levodopa as the first choice.
Katzenschlager R; Lees AJ
J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
[TBL] [Abstract][Full Text] [Related]
44. Ropinirole for levodopa-induced complications in Parkinson's disease.
Clarke CE; Deane KH
Cochrane Database Syst Rev; 2001; (1):CD001516. PubMed ID: 11279718
[TBL] [Abstract][Full Text] [Related]
45. Ropinirole as compared with levodopa in Parkinson's disease.
Hiner BC; Earnhart M
N Engl J Med; 2000 Sep; 343(12):884; author reply 885. PubMed ID: 11001684
[No Abstract] [Full Text] [Related]
46. [Ropinirol: a new dopamine agonist in the treatment of Parkinson's disease].
Giménez-Roldán S
Neurologia; 1997 Oct; 12(8):354-61. PubMed ID: 9471165
[TBL] [Abstract][Full Text] [Related]
47. A multicentre retrospective study of the clinical use of ropinirole in the treatment of Parkinson's disease: the ROPI-PARK study.
Valldeoriola F; Cobaleda S; Lahuerta J
Clin Neurol Neurosurg; 2009 Nov; 111(9):742-7. PubMed ID: 19733003
[TBL] [Abstract][Full Text] [Related]
48. Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations.
Hersh BP; Earl NL; Hauser RA; Stacy M
Mov Disord; 2010 May; 25(7):927-31. PubMed ID: 20461810
[TBL] [Abstract][Full Text] [Related]
49. Ropinirole in the treatment of restless legs syndrome.
Kakar RS; Kushida CA
Expert Rev Neurother; 2005 Jan; 5(1):35-42. PubMed ID: 15853472
[TBL] [Abstract][Full Text] [Related]
50. Bromocriptine: problems with low-dose de novo therapy in Parkinson's disease.
Grimes JD; Delgado MR
Clin Neuropharmacol; 1985; 8(1):73-7. PubMed ID: 3978651
[TBL] [Abstract][Full Text] [Related]
51. Ropinirole: a dopamine agonist for the treatment of Parkinson's disease.
Kuzel MD
Am J Health Syst Pharm; 1999 Feb; 56(3):217-24. PubMed ID: 10030505
[TBL] [Abstract][Full Text] [Related]
52. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study Group.
Korczyn AD; Brunt ER; Larsen JP; Nagy Z; Poewe WH; Ruggieri S
Neurology; 1999 Jul; 53(2):364-70. PubMed ID: 10430427
[TBL] [Abstract][Full Text] [Related]
53. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.
Inzelberg R; Schechtman E; Nisipeanu P
Drugs Aging; 2003; 20(11):847-55. PubMed ID: 12964891
[TBL] [Abstract][Full Text] [Related]
54. Pergolide : A Review of its Pharmacology and Therapeutic Use in Parkinson's Disease.
Markham A; Benfield P
CNS Drugs; 1997 Apr; 7(4):328-40. PubMed ID: 27520755
[TBL] [Abstract][Full Text] [Related]
55. [Advances in the medical treatment of Parkinson's disease].
Chaná P
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S22-5. PubMed ID: 20082996
[TBL] [Abstract][Full Text] [Related]
56. [1st long-term double-blind study of effectiveness and dyskinesia prevention of ropinirol].
Reichmann H; Lachenmayer L
Nervenarzt; 2000 Dec; 71(12):1012-4. PubMed ID: 11139984
[TBL] [Abstract][Full Text] [Related]
57. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease.
Rascol O; Lees AJ; Senard JM; Pirtosek Z; Montastruc JL; Fuell D
Clin Neuropharmacol; 1996 Jun; 19(3):234-45. PubMed ID: 8726542
[TBL] [Abstract][Full Text] [Related]
58. Switching from bromocriptine to ropinirole in patients with advanced Parkinson's disease: open label pilot responses to three different dose-ratios.
Giménez-Roldán S; Esteban EM; Mateo D
Clin Neuropharmacol; 2001; 24(6):346-51. PubMed ID: 11801810
[TBL] [Abstract][Full Text] [Related]
59. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis.
Etminan M; Gill S; Samii A
Drug Saf; 2003; 26(6):439-44. PubMed ID: 12688834
[TBL] [Abstract][Full Text] [Related]
60. Pharmacologic profile of ropinirole: a nonergoline dopamine agonist.
Tulloch IF
Neurology; 1997 Jul; 49(1 Suppl 1):S58-62. PubMed ID: 9222275
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
